Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lithium is a small molecule mood stabilizer primarily used to treat and prevent episodes of mania and depression in bipolar disorder. It is also prescribed for other psychiatric conditions such as schizophrenia and certain types of depression. The exact mechanism by which lithium exerts its mood-stabilizing effects is not fully understood; however, it is believed to modulate neurotransmitter activity in the central nervous system by decreasing norepinephrine release and increasing serotonin synthesis. Lithium has a narrow therapeutic index requiring regular blood monitoring to avoid toxicity. It may be used long-term for maintenance therapy in bipolar disorder[1][2][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lithium.